<SEC-DOCUMENT>0001171843-20-003603.txt : 20200512
<SEC-HEADER>0001171843-20-003603.hdr.sgml : 20200512
<ACCEPTANCE-DATETIME>20200511185158
ACCESSION NUMBER:		0001171843-20-003603
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200511
FILED AS OF DATE:		20200512
DATE AS OF CHANGE:		20200511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		20866520

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_051120.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 4pt 0 0"><B>UNITED STATES </B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 12pt 0 0"><B>FORM 6-K </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>Date of report: May 11, 2020</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 12pt 0 0"><B>Commission File Number: 001-38844 </B></P>

<P STYLE="font-size: 24pt; text-align: center; margin: 12pt 0 0"><B>GENFIT S.A. </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(Translation of registrant&rsquo;s name into English) </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>59120 Loos, France</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(Address of principal executive office) </B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9746; Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9;&#9744; Form 40-F</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0; font-size: 10pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT LIST</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 7%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 92%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><A HREF="exh_991.htm">99.1</A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm">Press Release dated May 11, 2020.</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font-size: 10pt; margin: 12pt 0 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="margin: 12pt 0 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-size: 10pt">Date: May 11, 2020</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: top; width: 27%"><FONT STYLE="font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD>
    <TD STYLE="vertical-align: top; width: 18%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: right; margin: 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html lang="en-US">
<head>
<title>EdgarFiling</title><meta content="text/html; charset=windows-1252" /><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" /></head>
<body bgcolor="#ffffff">

<p style="text-align: right;"><font style="font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="text-align: right"><font style="font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="text-align: center"><font style="font-size: 10pt"><b><img src="logo.jpg" alt="" style="height: 186px; width: 750px"></b></font></p>

<p style="text-align: center;"><font style="font-size: 10pt"><b>GENFIT: Announces Results from Interim Analysis of RESOLVE-IT
Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis</b></font><font style="font-size: 10pt"><ul type="disc"></font><li><font style="font-size: 10pt"><b>Elafibranor did not demonstrate a statistically significant effect on
                     the primary endpoint of NASH resolution without worsening of fibrosis</b><br />&#160;</font></li>

<li><font style="font-size: 10pt"><b>GENFIT will engage with regulatory authorities to determine next steps regarding the extension
phase evaluating the effect of elafibranor on clinical outcomes</b><br />&#160;</font></li>

<li><font style="font-size: 10pt"><b>Safety and tolerability of elafibranor was consistent with previously conducted studies </b><br />&#160;</font></li>

<li><font style="font-size: 10pt"><b>GENFIT to host investor calls in English on May 11, 2020 at 4:30pm EDT / 10:30pm CEST, and
in French on May 12, 2020 at 1:30am EDT / 7:30am CEST </b></font></li></ul>

<p align="justify"><font style="font-size: 10pt"><b>Lille (France), Cambridge (Massachusetts, United States), May 11, 2020 &#8211;
GENFIT (Nasdaq and Euronext: GNFT)</b>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with
metabolic and liver diseases, today announced results from an interim analysis of the RESOLVE-IT Phase 3 trial evaluating once-daily,
120mg of elafibranor in adults with non-alcoholic steatohepatitis (NASH).</font></p>

<p align="justify"><font style="font-size: 10pt">The trial did not meet the predefined primary endpoint of NASH resolution without
worsening of fibrosis in the ITT population of 1,070 patients. The response rate in the 717 patients enrolled on study drug was
19.2% for patients who received elafibranor 120mg compared to 14.7% for patients in the placebo arm. On the fibrosis key secondary
endpoint, 24.5% of patients who received elafibranor 120mg achieved fibrosis improvement of at least one stage compared to 22.4%
in the placebo arm. The other key secondary endpoint related to metabolic parameters did not achieve statistical significance.</font></p>

<p align="justify"><font style="font-size: 10pt"><b>Pascal Prigent, CEO of GENFIT</b>, stated: &#8220;<i>These results are highly
disappointing, not only for the GENFIT team, but also for patients and healthcare providers as there continues to be considerable
unmet medical need in the NASH space. The GENFIT team is actively reviewing the full interim dataset and will be conducting additional
analyses, to gain a clearer understanding of the higher than anticipated response rates in the placebo arm. We plan to share these
detailed findings with the regulatory authorities in the coming months and with their guidance, determine a final decision regarding
the continuation of the RESOLVE-IT trial. In parallel, we continue as planned with our NIS4<sup>TM</sup> and Phase 3 PBC (primary
biliary cholangitis) programs, which are independent of our NASH program with elafibranor. We will provide updated guidance on
our global corporate strategy later in the year, once we have more clarity on the regulatory implications of the RESOLVE-IT interim
readout, as well as more visibility on the evolution of the impact of the worldwide pandemic on our ongoing studies.&#8221;</i></font></p>

<p style="text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 33%">&nbsp;</td>
    <td style="width: 34%">&nbsp;</td>
    <td style="width: 33%">&nbsp;</td></tr>
</table>

<p style="text-align: justify"><font style="font-size: 10pt"><i></i></font></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"><IMG SRC="footer.jpg" ALT="" STYLE="height: 24px; width: 480px"></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 33%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="text-align: justify"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="text-align: center"><font style="font-size: 10pt"><b><img src="logo.jpg" alt="" style="height: 186px; width: 750px"></b></font></p>
<p style="text-align: justify"><font style="font-size: 10pt"><i>&nbsp;</i></font></p>

<p align="justify"><font style="font-size: 10pt"><b>Dr. Stephen Harrison, MD, Hepatologist, Medical Director of Pinnacle Clinical
Research, San Antonio, TX, (USA)</b> commented: &#8220;<i>NASH is a complicated, heterogeneous disease, and the results of the
RESOLVE-IT Phase 3 study of elafibranor in NASH demonstrate this significant hurdle</i>. <i>Placebo response was higher compared
to some other late phase trials, and it will be important for the field to understand variations across all trials.</i>&#8221;</font></p>

<p align="justify"><font style="font-size: 10pt"><b>INTERIM RESULTS </b></font></p>

<p align="justify"><font style="font-size: 10pt">The RESOLVE-IT Phase 3 trial evaluated the effect of elafibranor compared to
placebo in 1,070 patients (ITT population) with biopsy proven NASH as defined by NAS greater than or equal to 4, fibrosis stage
2 or 3. Patients were randomized 2:1 to receive elafibranor 120mg or placebo once daily, with a follow-up liver biopsy at week
72 to evaluate histologic endpoints (resolution of NASH without worsening of fibrosis or fibrosis improvement of at least one
stage). Patients with no biopsy results at week 72 were considered as non-responders in the efficacy analysis.</font></p>

<p align="justify"><font style="font-size: 10pt">The full dataset will be presented at one of the international hepatology congresses
that will take place in the second half of 2020.</font></p>

<p align="justify"><font style="font-size: 10pt"><b>Baseline characteristics</b></font></p>

<table style="margin-left:2.85pt; width:450.15pt; border-collapse:collapse !important;;border-collapse: collapse; ">
<tr>
    <td colspan="2" style="width:277.6px;;border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><font style="font-size: 10pt">&#160;</font></td>
    <td style="width:80px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; "><font style="font-size: 10pt">Statistics</font></td>
    <td style="width:80.87px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">Elafibranor</font></td>
    <td style="width:80.87px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">Placebo</font></td>
    <td style="width:80.87px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">Overall</font></td></tr>
<tr>
    <td colspan="2" style="width:277.6px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><font style="font-size: 10pt">ITT
    Set (F2-F3)</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">N</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">717</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">353</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">1070</font></td></tr>
<tr>
    <td colspan="2" style="width:277.6px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><font style="font-size: 10pt">Age
    (Years)</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">Mean
    (SD)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">54.35
    (12.06)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">55.04
    (11.10)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">54.58
    (11.75)</font></td></tr>
<tr>
    <td rowspan="2" style="width:120.27px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; "><font style="font-size: 10pt">Sex</font></td>
    <td style="width:157.34px;;border-right: solid black 1pt ; text-align: right ;  vertical-align: middle; "><font style="font-size: 10pt">Female</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; "><font style="font-size: 10pt">N(%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; "><font style="font-size: 10pt">283 (39.5)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; "><font style="font-size: 10pt">137 (38.8)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; "><font style="font-size: 10pt">420 (39.3)</font></td></tr>
<tr>
    <td style="width:157.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; "><font style="font-size: 10pt">Male</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">N(%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">434
    (60.5)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">216
    (61.2)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; "><font style="font-size: 10pt">650
    (60.7)</font></td></tr>
<tr>
    <td style="width:120.27px;;border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; "><font style="font-size: 10pt">Fibrosis
    Stage</font></td>
    <td style="width:157.34px;;border-right: solid black 1pt ; text-align: right ;  vertical-align: middle; "><font style="font-size: 10pt">Stage
    2</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; "><font style="font-size: 10pt">N (%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; "><font style="font-size: 10pt">338 (47.1)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; "><font style="font-size: 10pt">167 (47.3)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; "><font style="font-size: 10pt">505 (47.2)</font></td></tr>
<tr>
    <td style="width:120.27px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><font style="font-size: 10pt">&#160;</font></td>
    <td style="width:157.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; "><font style="font-size: 10pt">Stage
    3</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">N
    (%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">379
    (52.9)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">186
    (52.7)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">565
    (52.8)</font></td></tr>
<tr>
    <td style="width:120.27px;;border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; "><font style="font-size: 10pt">Type
    2 Diabetes</font></td>
    <td style="width:157.34px;;border-right: solid black 1pt ; text-align: right ;  vertical-align: middle; "><font style="font-size: 10pt">No</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">N (%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">361 (50.3)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">178 (50.4)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">539 (50.4)</font></td></tr>
<tr>
    <td style="width:120.27px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><font style="font-size: 10pt">&#160;</font></td>
    <td style="width:157.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; "><font style="font-size: 10pt">Yes</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">N
    (%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">356
    (49.7)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">175
    (49.6)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">531
    (49.6)</font></td></tr>
<tr>
    <td style="width:120.27px;;border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: top ; "><font style="font-size: 10pt">NAS</font></td>
    <td style="width:157.34px;;border-right: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><font style="font-size: 10pt">4</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">N (%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">104 (14.5)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">45 (12.7)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">149 (13.9)</font></td></tr>
<tr>
    <td style="width:120.27px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><font style="font-size: 10pt">&#160;</font></td>
    <td style="width:157.34px;;border-right: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><font style="font-size: 10pt">5</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">N (%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">209 (29.1)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">90 (25.5)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">299 (27.9)</font></td></tr>
<tr>
    <td style="width:120.27px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><font style="font-size: 10pt">&#160;</font></td>
    <td style="width:157.34px;;border-right: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><font style="font-size: 10pt">6</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">N (%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">239 (33.3)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">120 (34.0)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">359 (33.6)</font></td></tr>
<tr>
    <td style="width:120.27px;;border-right: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><font style="font-size: 10pt">&#160;</font></td>
    <td style="width:157.34px;;border-right: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><font style="font-size: 10pt">7</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">N (%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">146 (20.4)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">92 (26.1)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">238 (22.2)</font></td></tr>
<tr>
    <td style="width:120.27px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; "><font style="font-size: 10pt">&#160;</font></td>
    <td style="width:157.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><font style="font-size: 10pt">8</font></td>
    <td style="width:80px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">N
    (%)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">19
    (2.6)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">6
    (1.7)</font></td>
    <td style="width:80.87px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">25
    (2.3)</font></td></tr>
</table>

<p align="justify"><font style="font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="text-align: justify"><font style="font-size: 10pt"><b></b></font></p>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"><IMG SRC="footer.jpg" ALT="" STYLE="height: 24px; width: 480px"></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 33%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="text-align: justify"><font style="font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="text-align: center"><font style="font-size: 10pt"><b><img src="logo.jpg" alt="" style="height: 186px; width: 750px"></b></font></p>

<p style="text-align: justify"><font style="font-size: 10pt"><b>Interim efficacy results at week 72</b></font></p>

<table style="margin-left:2.85pt; width:396.9pt; border-collapse:collapse !important;;border-collapse: collapse; ">
<tr>
    <td colspan="2" rowspan="2" style="width:306.14px;;text-align: center ;  vertical-align: middle; "><font style="font-size: 10pt">ITT
    (missing biopsy = non-responder)</font></td>
    <td colspan="2" style="width:122.54px;;border-top: solid black 1pt ; border-right: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><font style="font-size: 10pt">Elafibranor
    120mg</font></td>
    <td colspan="2" style="width:122.6px;;border-top: solid black 1pt ; border-right: solid black 1pt ; text-align: center ;  vertical-align: middle; vertical-align: bottom ; "><font style="font-size: 10pt"><i>Placebo</i></font></td>
    <td rowspan="2" style="width:77.54px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; "><font style="font-size: 10pt"><i>P-Value</i></font></td></tr>
<tr>
    <td style="width:79.74px;;border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">N</font></td>
    <td style="width:42.8px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">%</font></td>
    <td style="width:75.4px;;border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">N</font></td>
    <td style="width:47.2px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">%</font></td></tr>
<tr>
    <td style="width:92.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">Primary
    Endpoint</font></td>
    <td style="width:213.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">NASH
    Resolution without worsening of fibrosis</font></td>
    <td style="width:79.74px;;border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">138/717</font></td>
    <td style="width:42.8px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">19.2</font></td>
    <td style="width:75.4px;;border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">52/353</font></td>
    <td style="width:47.2px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">14.7</font></td>
    <td style="width:77.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">0.0659</font></td></tr>
<tr>
    <td style="width:92.67px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">Key
    secondary Endpoint</font></td>
    <td style="width:213.47px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">Fibrosis
    improvement of at least one stage</font></td>
    <td style="width:79.74px;;border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">176/717</font></td>
    <td style="width:42.8px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">24.5</font></td>
    <td style="width:75.4px;;border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">79/353</font></td>
    <td style="width:47.2px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">22.4</font></td>
    <td style="width:77.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: bottom ; "><font style="font-size: 10pt">0.4457</font></td></tr>
</table>

<p align="justify"><font style="font-size: 10pt"><br>

No significant differences as compared to placebo were achieved on the key secondary
endpoints, including fibrosis improvement of at least one stage and changes in metabolic parameters (triglycerides, Non-HDL Cholesterol,
HDL Cholesterol, LDL Cholesterol, HOMA-IR in non diabetic patients, and HbA1c in diabetic patients).</font></p>

<p align="justify"><font style="font-size: 10pt"><b>Safety and tolerability results</b></font></p>

<p align="justify"><font style="font-size: 10pt">The safety and tolerability profile of elafibranor was similar to what has been
observed in our previously conducted trials.</font></p>

<p align="justify"><font style="font-size: 10pt"><b>Conference Call in English on May 11, 2020 at 4:30pm EDT /10:30pm CEST, and
in French on May 12, 2020 at 1:30am EDT / 7:30am CEST. </b>GENFIT will host a conference call to discuss the results of the Phase
3 RESOLVE-IT clinical trial.</font></p>

<p align="justify"><font style="font-size: 10pt">The English conference call will be accessible from the investor page of our
website, in the events section at <u>https://ir.genfit.com/</u>, or by calling 877-407-9167 (toll-free U.S. and Canada), 201-493-6754
(international) or 0 800 912 848 (France) ten minutes prior to the start time (no passcode needed). A replay will be available
shortly after the call.</font></p>

<p align="justify"><font style="font-size: 10pt">The French conference call will be accessible from the investor page of our website,
in the events section at <u>https://ir.genfit.com/</u>, or by calling 0805639972 (toll-free), or +33170709502&#160; (toll/local)
ten minutes prior to the start time (passcode required: 53637769#). A replay will be available shortly after the call.</font></p>

<p align="justify"><font style="font-size: 10pt"><b>ABOUT GENFIT</b></font></p>

<p align="justify"><font style="font-size: 10pt">GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and
development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable
unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based
drug discovery, with a rich history and strong scientific heritage spanning more than two decades. Its most advanced drug candidate,
elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial (&#8220;RESOLVE-IT&#8221;) as a potential treatment
for NASH and GENFIT plans to initiate a Phase 3 clinical trial of elafibranor in patients with PBC. As part of GENFIT&#8217;s
comprehensive approach to clinical management of patients with NASH, the Company is also developing a new, non-invasive blood-based
diagnostic test, NIS4&#153;, which, if approved, could enable easier identification of patients with NASH. With facilities in
Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 200 employees. GENFIT is a publicly traded company
listed on the Nasdaq Global Select Market and on compartment B of Euronext&#8217;s regulated market in Paris (Nasdaq and Euronext:
GNFT). <u>www.genfit.com</u><br /></font></p>

<p align="justify">&nbsp;</p>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"><IMG SRC="footer.jpg" ALT="" STYLE="height: 24px; width: 480px"></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 33%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="text-align: justify"></p>

<p style="text-align: justify"><font style="font-size: 10pt"><b>&nbsp;</b></font></p>
<p style="text-align: center"><font style="font-size: 10pt"><b><img src="logo.jpg" alt="" style="height: 186px; width: 750px"></b></font></p>

<p style="text-align: justify"><font style="font-size: 10pt"><b>FORWARD LOOKING STATEMENTS</b></font></p>

<p align="justify"><font style="font-size: 10pt">This press release contains certain forward-looking statements, including those
within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT, including statements about
our expected future performance, business prospects, events and plans, including timing of further analyses and the publication
of the full dataset of interim results of our Phase 3 RESOLVE-IT clinical trial, our expected clinical and regulatory strategy
for elafibranor, timing of clinical and regulatory milestones in our PBC and NIS4&#153; programs, our financial perspective, and
our ability to continue supporting activities and to minimize potential delays on our business once the COVID-19 pandemic subsides.
The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221;
and similar expressions, is intended to identify forward-looking statements.&#160; Although the Company believes its expectations
are based on the current expectations and reasonable assumptions of the Company&#8217;s management, these forward-looking statements
are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from
those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other
things, the uncertainties inherent in research and development, including related to safety, biomarkers, progression of, and results
from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates
and the Company&#8217;s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed
or identified in the Company&#8217;s public filings with the French Autorit&#233; des march&#233;s financiers (&#8220;AMF&#8221;),
including those listed in Section 4 &#8220;Main Risks and Uncertainties&#8221; of the Company&#8217;s 2018 Registration Document
filed with the AMF on February 27, 2019 under n&#176; D.19-0078, which is available on GENFIT&#8217;s website (www.genfit.com)
and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange
Commission (&#8220;SEC&#8221;), including the Company&#8217;s final prospectus dated March 26, 2019, and subsequent filings and
reports filed with the AMF or SEC, or otherwise made public, by the Company. In addition, even if the Company&#8217;s results,
performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or developments in future periods.&#160; These forward-looking
statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does
not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information,
future events or otherwise.</font></p>

<p align="justify">&nbsp;</p>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 33%"><IMG SRC="footer.jpg" ALT="" STYLE="height: 24px; width: 480px"></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 33%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="text-align: justify"></p>

<p style="text-align: justify"><font style="font-size: 10pt"><b>&nbsp;</b></font></p>
<p style="text-align: center"><font style="font-size: 10pt"><b><img src="logo.jpg" alt="" style="height: 186px; width: 750px"></b></font></p>

<p style="text-align: justify"><font style="font-size: 10pt"><b>CONTACT</b></font></p>

<p align="justify"><font style="font-size: 10pt"><b>GENFIT</b> | Investors</font></p>

<p align="justify"><font style="font-size: 10pt">Naomi EICHENBAUM &#8211; Investor Relations | Tel: +1 (617) 714 5252 | <u>investors@genfit.com</u><br /></font></p>

<p align="justify"><font style="font-size: 10pt"><b>PRESS RELATIONS </b>| Media</font></p>

<p align="justify"><font style="font-size: 10pt">H&#233;l&#232;ne LAVIN &#8211; Press relations | Tel: +333 2016 4000 | <u>helene.lavin@genfit.com</u><br /></font></p>

<p><font style="font-size: 10pt"><b>GENFIT</b> | 885 Avenue Eug&#232;ne Avin&#233;e, 59120 Loos - FRANCE | +333 2016 4000
| www.genfit.com</font></p>

<p><font style="font-size: 10pt">&#160;</font></p>




<p><font style="font-size: 10pt">&nbsp;</font></p>

<p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 33%"><IMG SRC="footer.jpg" ALT="" STYLE="height: 24px; width: 480px"></TD><td style="width: 34%">&nbsp;</TD><td style="font-size: 10pt; text-align: right; width: 33%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR>
</table></p>

<p><font style="font-size: 10pt">&nbsp;</font></p>

<p><font style="font-size: 10pt"></font></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #" P\# 2(  A$! Q$!_\0
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M':=AAIWW#_=' _K7GY-!RQ::Z79Z.:34<,T^MC:N[RWT^SEN[J58H(E+N[=
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M#I__ (,F_P#C5.^W^*?^@#I__@S;_P"-4<C_ *8>T79_<;I%,9:Q/MWBG_H
MZ?\ ^#)O_C5--_XH_P"@#I__ (,F_P#C5'(_Z8>T79_<;!&#3Q6";[Q1_P!
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M..34Z#BJT3;CFK24@)!3L4@IU( I*6FF@89HS244Q :2@FF[J '4N:9NI=U
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MKSV]Z]7U/P]I6K6$=C>6:/;Q?ZM%)39QCC&,5DV/P[\-V5RLZ6)D=3E1-(6
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MI1Y:,,A@.E $1ADC(,BD#U'-.N'SA?;H:GBF=T#/P!Z5)+<PW2!'1 XZ$=:
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M>J\)._KWHHH0'0Z0[D[2S%?3/%9FJHJW(VJ!\W8444+<"74N+&W X&*S8?\
M7J/>BB@#J]*.;T*>FWI5/6(HX[O*1JI/]T8HHI=2D8$OWVJ[:$AHL$CFBBF2
M6KX9O(_K4=QS?<^@HHH O61/VUN?X?Z4^XX@3']^BBD!H:I]^Q_W?ZUKV0'V
M2/@?=HHJH[A+8EP/04A ]!115$#"!Z"HR!Z"BB@9&P'H*80/0444F!&0,]*3
M ]*** ' #TI0*** $(&>E>Q?"K_D6I_^OMO_ $!***3&CT1/NBIUHHI#'TE%
M%(8T]*K3444T)D0I#113$+']^I^]%%)C%H-%% %:7[U(G6BB@"RO2GT44 (:
M0=:**8AZU*M%%(!PIU%% Q:***0!1110,*#110(2BBBF M(:** &FHVZ444
M0/3%HHJ)%1)5J&__ ./&3\/YBBBHELS2/Q(Y^7O38/\ 6445S+<ZI;&U;?=%
M6QTHHKJ6QQO<0]*KR@444F-&;.HW'@5 JC=T'Y445GU-31MQTK3C^[115P,I
$[G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  = D<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HK
M'UO6I--DM+2TMOM-]=L5BC+;5  R6)]!5#4-?U32]#DO+JVLO/69(U$<Q9"&
M[DXR*5T%CIZ*X^_\5ZCIVG6]PT%A=O+.R$6DQ==BKN//KUXJW=^*=DLAM(XY
M8/[-:^1R3DD'&#1= =+17)CQ)JD7AVYU:>'3V"1))&D,K,?F(X8=N#1-KGB!
M=8M]/CL].+7,;2Q%I7^X/7C@T7UL'F=915/4;J6TL1,@7?OC4@\CYG /\Z-4
MO&T_3I;E(PY3'!. ,D#)/H,Y/L*8%RBN?.O3I;3L4MG,<R1"X1SY/S=R>V._
MU'--D\03K;1G-G&S730>>[GR6 0MN!_#'US2N!T5%06DKR6B2S20NQ&2\)RA
M'J*S-/\ $$=Q#/+=)Y"(Z^6>3NC<X1O;/Z4^M@\S:HJE<ZM9VLKQ22,95V_(
MB,Q);.T  <DX/'M49URP$43[Y"979$C$+%RR]5VXR"/>BX&C15*VU6SNVB2*
M1M\F_:C(RD;" P((X()'6F2:U9(JD/)(69U"11,[?(<,< 9P#WHN!H45G:AJ
M@@T1M0M3'*I56C+'Y2&(&3^=%K?NNP7EQ:,TL@CB^S;B"V"<'KC@&CK8#1HJ
MC-J]G#(T9=WE63RO+CC9F+;0V  .>#G-4YM?MV2WEM7=E9B70VTA8H.&. ,C
M![D8.,4KH#:HK-FUVPA;:)))3Y:S'R86?"'.&X'3@TLVN6$+ -*S*45V=(V9
M45NA8@8 /O3 T:*IZI>M8V#2Q())F(2)"<!G8X IMGJEO=Q6ASLEN8RZH0>V
M-PSZ@GI0!>HK*&O60:XD:X7R(BBY6-R=Q9E].02N!C_"G_VW9^1-)F17B8*8
MI(G5RS?= 7&3GV!I70[&E165;ZS"-/CEN)2\Y?RFCCA<-YG7:$^]P/TYJ_:W
M<-[;B:!BR$D<@@@@X((/((/:F(FHK%359YM:GLTFL42*4)Y<CGS7&T,2!GW_
M $I+?6;B1K:>2&%;.ZF,,>'/F*<D D8QSCIVS23N!MT5F6>H75S>7T$EJL30
M!3&IDR6#9QN(X'3MGK56?6KRPDEBN[>!Y?*$D8@<XR7"!6R.Y(Y]CQ1<#=HK
M/L;VX>\FLKR.)9XT60-$2596R._0@@_I3]/OOM5I-/*%C$<TL9.>,(Q&?R%.
MX%VBL^#6[&<G$CQCRS*&EB9 R#JRE@,BFIKU@R2.SRQA$\S$L+H67.,J".>2
M.GJ* -*BH+6Z2[C+I',F#@B6)D/ZCFF:E=-8Z7=72*&:&)I IZ$@9H;L"U+5
M%8D]]J]M#;EULF>XF2),!\#()R?RH&M31V5^9H8FN;600J(F)25V V@9Y'+
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M1VL<4T<S2-%]ME/F KMYDQN!Z>HXJ_ID<]I,+462P0E&ED82M)\Y;@;F R<
MD_A6K13 Q]2LKS4&-O\ 9K5(3(CBY\TEP%(.0NW[W&.O^%1_V+YNKQW!L[6W
MBAF,N]'+/(W.., +UR>N36Y12L!GK:7,-]J%U%Y3--&@B5F(&Y0WWN.!DCIF
MLQ-)U.:SGBN8K1;B4K(URMPSEG5@RC:8QA>.@/'O71T46 S;&UNCJ$]_>)%'
M(\:1)'$Y<!02<DD#DD^G:JD.G:BMK=Z?)%:_9;B28^<MPV]5<L?N;,9&?[U;
MM%%@.>GT>^U*&."\\B%(;=XE:)RY=F7;G! P,=N:DDT^_O)5FO+6S;R8&B6'
MS25E+;<DG;\HPO'!ZUNT4[ 9>EV-S!;W$5TQ6*1OW<0G:0QKC!&\X/7/TI]W
MI@;1+O3[8D&:)T4S2,^"PQR3DXK1HI-7!:&)<>&[)X+:&"QLHT6=))U$*@2!
M0>" .>O>H4\.R"5+0NB:5%,T\212,D@8CA<KC !+$$'TKH:*=@,*/0YK:X"0
M2@VBW:W*B61F<':0XR<YR<'KW-0R^&G>]O%695L9[=TC09W1.S!C@=-N1GZD
MUT=%*P&-/#J]]I=U8W$%HC26[QB9)V(9B, [=G _$X]ZL:7;36P99;"RM1M
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C9TXZ?*:U**?F'D4M*M)+'3H[>4J75G)*GCEB?ZT5=HH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
